Rifampicin

Generic Name
Rifampicin
Brand Names
Isonarif, Rifadin, Rifamate, Rifater, Rofact
Drug Type
Small Molecule
Chemical Formula
C43H58N4O12
CAS Number
13292-46-1
Unique Ingredient Identifier
VJT6J7R4TR
Background

A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication

Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions
Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
Associated Therapies
Antibacterial therapy

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

Phase 1
Completed
Conditions
Interventions
First Posted Date
2023-06-15
Last Posted Date
2024-04-05
Lead Sponsor
Shanghai Henlius Biotech
Target Recruit Count
20
Registration Number
NCT05902728
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

First Posted Date
2023-06-12
Last Posted Date
2024-12-04
Lead Sponsor
Bellus Health Inc. - a GSK company
Target Recruit Count
42
Registration Number
NCT05899829
Locations
🇨🇦

GSK Investigational Site, Quebec City, Quebec, Canada

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

First Posted Date
2023-04-24
Last Posted Date
2023-08-21
Lead Sponsor
Insmed Incorporated
Target Recruit Count
32
Registration Number
NCT05826574
Locations
🇺🇸

USA001, Dallas, Texas, United States

PanACEA - STEP2C -01

First Posted Date
2023-04-11
Last Posted Date
2024-04-17
Lead Sponsor
Michael Hoelscher
Target Recruit Count
270
Registration Number
NCT05807399
Locations
🇲🇼

Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi

🇹🇿

Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania

🇺🇬

Makerere University Lung Institute Limited, Kampala, Uganda

and more 5 locations

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

First Posted Date
2023-03-13
Last Posted Date
2024-01-08
Lead Sponsor
Centers for Disease Control and Prevention
Target Recruit Count
288
Registration Number
NCT05766267
Locations
🇺🇸

TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States

🇺🇸

TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States

🇺🇸

TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States

and more 9 locations

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

First Posted Date
2023-02-09
Last Posted Date
2023-03-01
Lead Sponsor
Hutchmed
Target Recruit Count
28
Registration Number
NCT05720767
Locations
🇺🇸

PPD Austin, Austin, Texas, United States

A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

First Posted Date
2023-01-17
Last Posted Date
2023-12-07
Lead Sponsor
Zhejiang ACEA Pharmaceutical Co. Ltd.
Target Recruit Count
37
Registration Number
NCT05685719
Locations
🇨🇳

Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang, China

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-12-02
Last Posted Date
2024-03-20
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Target Recruit Count
31
Registration Number
NCT05635110
Locations
🇦🇺

CMAX Clinical Research, Adelaide, Australia

Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines

First Posted Date
2022-10-24
Last Posted Date
2024-01-05
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT05592223
Locations
🇺🇸

Fred Hutchinson Cancer Center, Seattle, Washington, United States

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-10-13
Last Posted Date
2024-11-21
Lead Sponsor
Amgen
Target Recruit Count
14
Registration Number
NCT05577624
Locations
🇺🇸

Covance Clinical Research Unit, Inc 3402 Kinsman Boulevard, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath